GSK Pharmaceuticals' EBITDA in India FY 2015-2022
In fiscal year 2022, GlaxoSmithKline Pharmaceuticals Limited in India had 7.56 billion Indian rupees as earnings before interest, tax, depreciation and amortization. This was an increase compared to the previous fiscal year's 5.98 billion rupees worth EBITDA.